莫西沙星序贯治疗老年社区获得性肺炎的疗效研究

Sequential moxifloxacin therapy in treatment of elderly patients with community-acquired pneumonia

目的研究莫西沙星序贯治疗老年社区获得性肺炎的疗效，安全性和治疗费用。方法80例老年社区获得性肺炎患者先予以莫西沙星注射液400mg／250ml静脉滴注，每天1次，治疗5～7d。临床症状改善后，随机分成序贯组和对照组。序贯组40例改口服莫西沙星片荆400mg，每天1次。对照组40例继续静脉滴注莫西沙星注射液400mg／250m1，每天1次。两组总疗程10d。观察疗效、药物的不良反应和治疗费用。结果两组的有效率无明显差异（P〉0．05），分别为90．00％和92．50％。两组细菌清除率分别为88．23％和88．89％，无明显差异（P〉0．05）。序贯组的治疗费用、不良反应均明显低于对照组（P〈0．05）。结论莫西沙星序贯治疗老年社区获得性肺炎疗效确切、安全，且节约费用。

Objective To evaluate the efficacy, safety and cost of sequential moxifloxaein therapy in elder patients with community acquired pneumonia compared with moxifloxacin injection. Methods 80 elder patients with community acquired pneumonia were randomly divided into two groups, which were treated with moxifloxacin injection followed by tablet （sequential group） or moxifloxaein injection group （control group）. Results The effective rate for the sequential group was 90.00%. While for the control group was 92.50%. There was no statistically significant difference between the two groups （P〉0.05）. The bacterial eradication rate in the two groups was 88. 23% and 88. 89%, respectively. There was also no significant difference between the two group （P〉0.05）. The average cost and the incidence of adverse drug reaction of the sequential group was lower than that of the control group. Conclusion The sequential moxifloxacin therapy for CAP is safe, effective, and cost-saved compared with full-course moxifloxacin infusion.